Compare Amphastar Pharmaceuticals Inc (AMPH) vs Coursera Inc (COUR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Coursera Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Coursera Inc trades at $5.72 (market cap $1.64B). The key difference: Coursera Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| AMPH | COUR | |
|---|---|---|
Market Cap | $826.08M | $1.64B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $12.70 |
52-Week Low | $16.87 | $5.09 |
Enterprise Value | $1.22B | $890.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Coursera (COUR) trades at $5.71, up 0.71% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $757.5M in 2025, though net losses persist at -$51M. The Udemy merger and a $500M share repurchase program are key developments. Cash flow from operations remains positive at $108.7M, supporting ongoing investments.
Wall Street analysts are generally optimistic with a $8.00 consensus price target, implying 40% upside. Risks include sustained profitability challenges and integration execution post-merger. The stock presents a growth opportunity if operational synergies materialize, but investors should weigh the high volatility and competitive pressures in edtech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
